Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors

Clinical Trial ID NCT00077454

PubWeight™ 3.24‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00077454

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The rationale for targeted therapies in medulloblastoma. Neuro Oncol 2013 0.92
2 Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. Stem Cells Int 2016 0.81
3 Advances in paediatric cancer treatment. Transl Pediatr 2014 0.76
4 Exogenous HGF Bypasses the Effects of ErbB Inhibition on Tumor Cell Viability in Medulloblastoma Cell Lines. PLoS One 2015 0.75
Next 100